# Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

**Authors:** Simron Singh, Diego Ferone, Jaume Capdevila, Jennifer Ang Chan, Wouter W. de Herder, Daniel Halperin, Josh Mailman, Lisa Hellström, Hanna Liedman, Agneta Svedberg, Fredrik Tiberg

PMC · DOI: 10.1186/s13063-024-08146-1 · 2024-05-02

## Full-text entities

- **Diseases:** GEP-NET (MESH:C535650)
- **Chemicals:** octreotide (MESH:D015282)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC11064387